Northern Trust Corp Neu Base Therapeutics, Inc. Transaction History

Northern Trust Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$4.63 - $7.34 $589,676 - $934,822	-127,360 Reduced 69.87%	54,926 $263,000
Q1 2021 May 12, 2021	SELL	$6.92 - $12.36 $110,443 - $197,265	-15,960 Reduced 8.05%	182,286 $1.35 Million
Q4 2020 Feb 11, 2021	BUY	$6.92 - $9.25 $24,199 - $32,347	3,497 Added 1.8%	198,246 $1.39 Million
Q3 2020 Nov 16, 2020	BUY	$7.25 - $9.71 $5,452 - $7,301	752 Added 0.39%	194,749 $1.48 Million
Q2 2020 Aug 14, 2020	BUY	$6.69 - $11.51 $1.3 Million - $2.23 Million	193,997 New	193,997 $1.7 Million

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.